124 related articles for article (PubMed ID: 9030388)
1. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.
Merry C; Mulcahy F; Barry M; Gibbons S; Back D
AIDS; 1997 Feb; 11(2):268-9. PubMed ID: 9030388
[No Abstract] [Full Text] [Related]
2. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
3. Double protease inhibitor regimens with amprenavir show promise.
AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
[No Abstract] [Full Text] [Related]
4. Head-to-head study of protease inhibitors.
AIDS Patient Care STDS; 1998 Jan; 12(1):63-4. PubMed ID: 11361890
[No Abstract] [Full Text] [Related]
5. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
6. Data in from first head-to-head protease inhibitor.
AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
[No Abstract] [Full Text] [Related]
7. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
10. Response of HIV-associated thrombocytopenia to triple agent antiretroviral therapy.
Walsh JC; Costello CE; Nelson MR
AIDS; 1997 Mar; 11(3):399-400. PubMed ID: 9147442
[No Abstract] [Full Text] [Related]
11. Saquinavir: major study shows survival benefit in treatment-naive patients.
James JS
AIDS Treat News; 1997 Jul; (No 274):6. PubMed ID: 11364463
[TBL] [Abstract][Full Text] [Related]
12. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
13. A patient's guide to protease inhibitors.
Elperin A; Sax P
AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
[TBL] [Abstract][Full Text] [Related]
14. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
[TBL] [Abstract][Full Text] [Related]
15. Saquinavir as Fortovase: why does it matter?
Trapnell CB
AIDS Clin Care; 1998 May; 10(5):37, 40. PubMed ID: 11365428
[TBL] [Abstract][Full Text] [Related]
16. From grapefruit juice to ritonavir.
TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093
[No Abstract] [Full Text] [Related]
17. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Klaus BD; Grodesky MJ
Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
[No Abstract] [Full Text] [Related]
18. Co-trimoxazole administered for Pneumocystis carinii pneumonia prophylaxis does not interfere with saquinavir pharmacokinetics.
Maserati R; Villani P; Cocchi L; Regazzi MB
AIDS; 1998 May; 12(7):815-6. PubMed ID: 9619815
[No Abstract] [Full Text] [Related]
19. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K
Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763
[No Abstract] [Full Text] [Related]
20. Garlic supplements found to lower saquinavir levels.
TreatmentUpdate; 2001; 12(12):17-8. PubMed ID: 11570085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
